Developing a safe, convenient, disease-modifying treatment for peanut allergy
RESEARCH AND DEVELOPMENT
May 28, 2019
Data show that PVX108 demonstrates exceptional safety in adults with peanut allergy
May 28, 2019, Melbourne, Victoria – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present...